C. diff Infection in Crohn's Disease: A Patient Guide

If you have Crohn's disease and a sudden bout of watery diarrhea lands you back in the bathroom every hour, your first thought is probably "flare." But there is another possibility that every Crohn's patient should know about: C. diff infection in Crohn's disease - a bacterial gut infection that mimics a flare almost perfectly, yet requires completely different treatment. A 2025 meta-analysis of roughly 800,000 patients found that nearly 9% of people with IBD harbor Clostridioides difficile at any given time (1), and antibiotic use alone can raise your risk up to 10-fold (6). Knowing the difference between a flare and an infection can change the entire course of your care.

Key Takeaways

• C. difficile infection (CDI) affects approximately 8.84% of IBD patients globally, with the highest prevalence in Asia at roughly 11% (1)
• Standard PCR testing can overdiagnose CDI in Crohn's patients - only 15.2% of screen-positive IBD patients had actual toxin detected, versus 36.1% of non-IBD patients (5)
• The ACG recommends testing every IBD patient who develops new diarrhea for C. diff before assuming it is a flare (2)
• First-line treatment is oral vancomycin for 14 days, with fidaxomicin preferred by IDSA/SHEA guidelines for both initial and recurrent episodes (2, 3)
• Fecal microbiota transplant (FMT) is recommended after the second CDI recurrence but is not endorsed for treating Crohn's disease itself (4)
• Hand washing with soap and water is essential - alcohol-based hand sanitizers do not kill C. diff spores (6)

What Is C. difficile and Why Does It Matter for Crohn's Patients?

Clostridioides difficile (formerly Clostridium difficile, commonly called C. diff) is a spore-forming bacterium that causes infection when it overgrows in the colon and produces toxins that damage the intestinal lining. For Crohn's patients, CDI matters more than it does for the general population because it can look identical to a disease flare - but treating it as a flare by increasing immunosuppression can make the infection worse.

The bacteria behind the infection

In a healthy gut, trillions of beneficial bacteria keep C. diff in check, even if the spores are present. Problems begin when that protective microbial community is disrupted. The CDC notes that C. diff spores can survive on surfaces for months to years and are transmitted through the fecal-oral route in healthcare facilities and the community alike (6). Antibiotics are the single biggest trigger: they wipe out the good bacteria that compete with C. diff, giving it room to multiply and produce tissue-damaging toxins. The CDC estimates that antibiotic use raises CDI risk up to 10-fold during treatment and in the month that follows (6).

How CDI differs from a Crohn's flare

The tricky part is that CDI and a Crohn's flare share the same headline symptoms - watery diarrhea, abdominal cramping, fever, and fatigue. But the underlying cause and treatment are fundamentally different. A flare calls for immune suppression to calm the overactive immune response, while CDI requires antibiotics to clear the infection. Escalating biologics or steroids during an undiagnosed C. diff infection can worsen the infection and delay recovery. This is precisely why guidelines now recommend testing for C. diff before assuming any new bout of diarrhea in a Crohn's patient is a flare (2). As we covered in our guide on understanding flares and remission, the symptoms can be remarkably similar - which is why lab confirmation matters.

Why Crohn's Patients Are at Higher Risk

Crohn's patients face a higher baseline risk of CDI than the general population, and the reasons stack on top of each other in ways that matter clinically.

Dysbiosis, immunosuppression, and healthcare exposure

Even before any medication enters the picture, Crohn's disease itself creates a state of gut dysbiosis - a less diverse, less stable microbial community that is less capable of keeping opportunistic organisms like C. diff in check. Layer on the medications many of us take - corticosteroids, biologics, immunomodulators - and the gut's defenses thin further. Add frequent antibiotic courses for infections or complications, recurring hospitalizations where C. diff exposure is highest, prior bowel surgeries, and colonic involvement, and the cumulative risk becomes clear.

The CDC identifies age 65 and older, healthcare exposure, and immunosuppression as independent risk factors for CDI in any patient (6). Crohn's patients often check two or three of those boxes simultaneously.

Global prevalence in IBD

A 2025 systematic review and meta-analysis by Amakye et al. pooled data from 28 studies covering approximately 800,000 patients and found an overall CDI prevalence of 8.84% in IBD (95% CI 5.91-13.03%) (1). Regionally, Asia reported the highest rates at roughly 11%, followed by Europe at approximately 7.92% and North America at about 7.85% (1). These numbers tell us that CDI in IBD is not a niche problem or a regional one - it is a global concern that affects roughly one in eleven IBD patients.

Diagnosing CDI: Why Testing Is Tricky in IBD

Diagnosing C. diff sounds straightforward - test the stool, get a result - but for Crohn's patients, the standard testing approach has a significant blind spot that can lead to overdiagnosis and unnecessary treatment.

Toxin EIA vs PCR vs two-step testing

There are two main stool tests for C. diff. PCR (also called NAAT) detects the gene that codes for the toxin and is very sensitive - but that sensitivity is a double-edged sword. It picks up patients who carry the organism without having active infection (colonization). Toxin EIA, on the other hand, detects the actual toxin protein and is more specific for true, tissue-damaging infection.

A 2022 study published in Gut Pathogens found a striking difference between IBD and non-IBD patients: among those who screened positive on the initial test, only 15.2% of IBD patients had detectable toxin compared to 36.1% of non-IBD patients (p value less than 0.0001) (5). Even more importantly, toxin-positive and toxin-negative IBD patients had no significant difference in colectomy, ICU admission, or 30-day mortality (5). This means that many IBD patients who test positive by PCR alone may be colonized but not actively infected - and treating them with antibiotics would add risk without clear benefit.

When to test during a flare

The ACG guidelines recommend testing every IBD patient who presents with a new flare of diarrhea for C. diff (2). Two-step testing - starting with NAAT/PCR and then confirming with toxin EIA - helps avoid overtreating colonization as active infection. This is especially important in Crohn's, where unnecessary antibiotics can further disrupt the microbiome and paradoxically increase future CDI risk.

Symptoms that should prompt testing include new or worsening watery diarrhea, fever, abdominal pain, and elevated white blood cell count, especially if you have recently taken antibiotics or been hospitalized. If your doctor has not mentioned C. diff testing during a suspected flare, it is reasonable to ask about it.

Treatment: What the Guidelines Say in 2026

Several major medical societies have updated their CDI treatment guidelines in recent years, and the recommendations are converging on a few key points that Crohn's patients should understand.

First-line treatment

The 2021 ACG guideline issues a strong recommendation for oral vancomycin at 125 mg four times daily for 14 days as first-line therapy for CDI in IBD patients (2). Metronidazole (Flagyl), which was once the standard, is no longer recommended as first-line because of lower cure rates and higher recurrence.

The 2021 IDSA/SHEA focused update goes a step further, expressing a preference for fidaxomicin over vancomycin for both initial and recurrent CDI episodes (conditional recommendation, moderate certainty of evidence) (3). Fidaxomicin has a narrower spectrum of activity, meaning it causes less collateral damage to the remaining healthy gut bacteria - a meaningful advantage for Crohn's patients whose microbiome is already compromised. The update also suggests bezlotoxumab, a monoclonal antibody, as an add-on therapy for patients who have had a CDI recurrence within six months, though it should be used with caution in patients with heart failure (3).

Recurrent CDI

Recurrence is one of the most frustrating aspects of CDI. First-recurrence rates in the general population run around 20-25% after initial treatment, and the rates are likely higher in immunosuppressed patients. Each recurrence makes the next one more likely, creating a cycle that can be difficult to break.

FMT and newer microbiome therapies

For patients who experience a second recurrence (their third CDI episode), the 2024 AGA guideline on fecal microbiota-based therapies recommends fecal microbiota transplant (FMT) or FDA-approved microbiome therapies such as RBL (REBYOTA) and SER-109 (VOWST) in select patients (4). FMT works by restoring a healthy microbial community that can outcompete C. diff. As we explored in our article on FMT for Crohn's disease, the procedure involves transplanting stool from a healthy donor into the patient's colon.

An important caveat: the AGA explicitly does not recommend FMT for treating IBD itself outside of clinical trials, even though it endorses the procedure for recurrent CDI (4). These are different indications with different levels of evidence.

During active CDI, your gastroenterologist will generally avoid escalating biologics or corticosteroids until the infection is under control. This requires careful coordination - the infection needs to clear, but the underlying Crohn's still needs management.

How CDI Affects Long-Term Crohn's Outcomes

A single CDI episode is more than a temporary setback. Research associates CDI in IBD patients with longer hospital stays, more frequent flares, and a higher burden of disease over time (1).

Impact on flares, hospitalization, and surgery

CDI can trigger or worsen an IBD flare, which may then prompt escalation of immunosuppressive therapy, which in turn raises the risk of future CDI. This creates a self-reinforcing cycle that is difficult to escape without early recognition and proper treatment. The inflammatory damage from CDI can also complicate surgical planning and recovery for patients who are already considering bowel resection.

Mortality and recurrence risk

While mortality from CDI has improved with better treatments, the infection remains a serious concern for immunocompromised patients. Recurrence is the primary long-term challenge: each episode damages the microbiome further, making the next recurrence more likely. Breaking that cycle - through appropriate testing, targeted antibiotics, and microbiome restoration when needed - is the key to protecting long-term outcomes.

Prevention: What Patients Can Do

Prevention is always better than treatment, and there are concrete steps Crohn's patients can take to lower their CDI risk.

Antibiotic stewardship

Not every infection requires antibiotics, and the choice of antibiotic matters. Broad-spectrum agents like clindamycin, fluoroquinolones, and cephalosporins carry the highest CDI risk (6). When your doctor prescribes antibiotics for a non-IBD condition - a sinus infection, a dental procedure, a urinary tract infection - it is worth asking whether a narrower-spectrum option would work. As we discussed in our article on the impact of antibiotics on Crohn's disease, the Crohn's and Colitis Foundation recommends that IBD patients be especially cautious about unnecessary antibiotic exposure (7).

Hand hygiene and environment

This is one area where Crohn's patients should know something the general public often does not: alcohol-based hand sanitizers do not kill C. diff spores (6). Only hand washing with soap and water physically removes the spores. This matters most after using the bathroom, before meals, and during or after a hospital stay. If a household member has had CDI, cleaning frequently touched surfaces with bleach-based products can help reduce environmental spore burden.

The probiotic question

Many patients ask whether probiotics can prevent CDI, and the honest answer is that the evidence is mixed. Some studies in the general population suggest a modest benefit, but major guidelines do not specifically endorse probiotics for CDI prevention in IBD patients. The strains studied, doses used, and patient populations vary widely across trials, making it difficult to draw firm conclusions. If you are interested in probiotics, our overview of probiotics and prebiotics for gut health covers the broader landscape - but discuss any specific product with your gastroenterologist before starting.

When to call the doctor

New watery diarrhea - especially if it comes with fever, abdominal pain, or develops within weeks of taking antibiotics or leaving the hospital - should prompt a call to your gastroenterologist. Do not assume it is a flare. Testing is quick, and early diagnosis means faster, more targeted treatment.

Frequently Asked Questions

How can I tell if my diarrhea is a Crohn's flare or a C. diff infection?

You often cannot tell by symptoms alone - both cause watery diarrhea, cramping, and fatigue. The key difference is in the lab. Current guidelines recommend stool testing for C. diff in every IBD patient who develops new or worsening diarrhea (2). Two-step testing (PCR followed by toxin confirmation) gives the most reliable answer in IBD patients.

Is C. diff dangerous for Crohn's patients?

CDI in Crohn's patients is associated with longer hospital stays, more frequent flares, and a self-reinforcing cycle of infection, inflammation, and immunosuppression (1). While most cases respond to treatment, recurrence is common and the cumulative burden is higher than for the general population. Early detection is the best way to limit the impact.

Can I get C. diff without taking antibiotics?

Yes. While antibiotics are the biggest risk factor, Crohn's patients can develop CDI from other causes of microbial disruption - including immunosuppressive medications, hospitalization, and the dysbiosis that Crohn's disease itself creates (1, 6). Any new diarrheal episode in a Crohn's patient warrants consideration of CDI testing.

What is the difference between vancomycin and fidaxomicin for C. diff?

Both are oral antibiotics used to treat CDI. Vancomycin (125 mg four times daily for 14 days) is the established first-line therapy recommended by the ACG (2). Fidaxomicin is preferred by the IDSA/SHEA update because it has a narrower spectrum, causing less damage to the healthy gut bacteria and potentially reducing recurrence risk (3). Availability and cost vary by country and insurance coverage.

When is FMT recommended for C. diff?

The 2024 AGA guideline recommends fecal microbiota transplant or FDA-approved microbiome therapies (such as REBYOTA or VOWST) after the second CDI recurrence - meaning the third episode overall - in select patients (4). It is important to note that FMT is recommended specifically for recurrent CDI, not as a treatment for Crohn's disease itself.

Does hand sanitizer kill C. diff?

No. Alcohol-based hand sanitizers do not kill C. diff spores (6). You need to wash your hands with soap and water to physically remove the spores. This is especially important after using the bathroom, before eating, and during any hospital visit or stay.

Should I ask my doctor to test for C. diff during a flare?

Absolutely. The ACG specifically recommends C. diff testing for every IBD patient presenting with new diarrhea (2). If your doctor has not mentioned testing, it is a reasonable and important question to ask. The test is simple - a stool sample - and catching CDI early can prevent unnecessary escalation of immunosuppressive therapy and speed your recovery.

References

1. Amakye, D.K., et al. Global Patterns of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Prevalence, Epidemiology, and Risk Factors. Crohn's & Colitis 360, 2025. Read study
2. Kelly, C.R., et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol, 2021;116(6):1124-1147. Read guideline
3. Johnson, S., et al. SHEA/IDSA 2021 Clinical Practice Guideline Update for the Management of Clostridioides difficile Infection in Adults. IDSA, 2021. Read guideline
4. American Gastroenterological Association. AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases. 2024. Read guideline
5. Bernard, C.K., et al. Clostridioides difficile toxin is infrequently detected in inflammatory bowel disease and does not associate with clinical outcomes. Gut Pathogens, 2022. Read study
6. Centers for Disease Control and Prevention. About C. diff. 2024. Read article
7. Crohn's & Colitis Foundation. Antibiotics Fact Sheet. 2023. Read fact sheet